Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2021 / N 4

Фибрилляция предсердий у пациента с метаболическими нарушениями
С.Н. Терещенко, Н.В. Сафронова, И.В. Жиров

Список литературы

1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M, DeCleene N, Eagle KA, Emmons-Bell S, Feigin VL, Fernández-Solà J, Fowkes G, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum N, Koroshetz W, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Temesgen AM, Mokdad A, Moran AE, Muntner P, Narula J, Neal B, Ntsekhe M, de Oliveira GM, Otto C, Owolabi M, Pratt M, Rajagopalan S, Reitsma M, Ribeiro ALP, Rigotti N, Rodgers A, Sable C, Shakil S, Sliwa-Hahnle K, Stark B, Sundström J, Timpel P, Tleyjeh IM, Valgimigli M, Vos T, Whelton PK, Yacoub M, Zuhlke L, Murray C, Fuster V; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. Journal of the American College of Cardiology 2020 Dec;76(25):2982-3021.
2. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D’Agostino RB, Murabito JM, Kannel WB, Benjamin EJ. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003 Jun;107(23):2920-5.
3. Emdin CA, Wong CX, Hsiao AJ, Altman DG, Peters SA, Woodward M, Odutayo AA. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies. BMJ 2016 Jan;532:h7013.
4. Karam BS, Chavez-Moreno A, Koh W, Akar JG, Akar FG. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes. Cardiovascular Diabetology 2017 Sep;16(1):120.
5. Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GYH. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. Journal of Thrombosis and Haemostasis 2011 Jan;9(1):39-48.
6. Fumagalli S, Said SA, Laroche C, Gabbai D, Boni S, Marchionni N, Boriani G, Maggioni AP, Musialik-Lydka A, Sokal A, Petersen J, Crijns HJGM, Lip GYH; EORP-AF General Pilot Registry Investigators. Management and prognosis of atrial fibrillation in diabetic patients: an EORP-AF General Pilot Registry report. European Heart Journal. Cardiovascular Pharmacotherapy 2018 Jul;4(3):172-9.
7. Echouffo-Tcheugui JB, Shrader P, Thomas L, Gersh BJ, Kowey PR, Mahaffey KW, Hylek EM, Go AS, Peterson ED, Piccini JP, Fonarow GC. Care patterns and outcomes in atrial fibrillation patients with and without diabetes: ORBIT-AF registry. Journal of American College of Cardiology 2017 Sep;70(11):1325-35.
8. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994 Mar;271(11):840-4.
9. Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. The American Journal of Cardiology 2011 Jul;108(1):56-62.
10. Dublin S, Glazer NL, Smith NL, Psaty BM, Lumley T, Wiggins KL, Page RL, Heckbert SR. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. Journal of General Internal Medicine 2010 Aug;25(8):853-8.
11. Du X, Ninomiya T, de Galan B, Abadir E, Chalmers J, Pillai A, Woodward M, Cooper M, Harrap S, Hamet P, Poulter N, Lip GYH; ADVANCE Collaborative Group. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. European Heart Journal 2009 May;30(9):1128-35.
12. Russo I, Frangogiannis NG. Diabetes-associated cardiac fibrosis: cellular effectors, molecular mechanisms and therapeutic opportunities. Journal of Molecular and Cell Cardiology 2016 Jan;90:84-93.
13. Liu C, Fu H, Li J, Yang W, Cheng L, Liu T, Li G. Hyperglycemia aggravates atrial interstitial fibrosis, ionic remodeling and vulnerability to atrial fibrillation in diabetic rabbits. Anadolu Kardiyoloji Dergisi 2012 Nov;12(7):543-50.
14. Kato T, Yamashita T, Sekiguchi A, Tsuneda T, Sagara K, Takamura M, Kaneko S, Aizawa T, Fu LT. AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. Journal of Cardiovascular Electrophysiology 2008 Apr;19(4):415-20.
15. Jia G, Whaley-Connell A, Sowers JR. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia 2018 Jan;61(1):21-8.
16. Tiwari S, Schirmer H, Jacobsen BK, Hopstock LA, Nyrnes A, Heggelund G, Njølstad I, Mathiesen EB, Løchen ML. Association between diastolic dysfunction and future atrial fibrillation in the Tromsø Study from 1994 to 2010. Heart (British Cardiac Society) 2015 Aug;101(16):1302-8.
17. Watanabe M, Yokoshiki H, Mitsuyama H, Mizukami K, Ono T, Tsutsui H. Conduction and refractory disorders in the diabetic atrium. American Journal of Physiology. Heart and Circulatory Physiology 2012 Jul;303(1):H86-95.
18. Chao TF, Suenari K, Chang SL, Lin YJ, Lo LW, Hu YF, Tuan TC, Tai CT, Tsao HM, Li CH, Ueng KC, Wu TJ, Chen SA. Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose. The American Journal of Cardiology 2010 Dec;106(11):1615-20.
19. Ayhan S, Ozturk S, Alcelik A, Ozlu MF, Erdem A, Memioglu T, Ozdemir M, Yazici M. Atrial conduction time and atrial mechanical function in patients with impaired fasting glucose. Journal of Interventional Cardiac Electrophysiology 2012 Dec;35(3):247-52; discussion 252.
20. Demir K, Avci A, Kaya Z, Marakoglu K, Ceylan E, Yilmaz A, Ersecgin A, Armutlukuyu M, Altunkeser BB. Assessment of atrial electromechanical delay and P-wave dispersion in patients with type 2 diabetes mellitus. Journal of Cardiology 2016 Apr;67(4):378-83.
21. De Vos CB, Weijs B, Crijns HJGM, Cheriex EC, Palmans A, Habets J, Prins MH, Pisters R, Nieuwlaat R, Tieleman RG. Atrial tissue Doppler imaging for prediction of new-onset atrial fibrillation. Heart (British Cardiac Society) 2009 May;95(10):835-40.
22. Kuehl M, Stevens MJ. Cardiovascular autonomic neuropathies as complications of diabetes mellitus. Nature Reviews. Endocrinology 2012 Feb;8(7):405-16.
23. Otake H, Suzuki H, Honda T, Maruyama Y. Influences of autonomic nervous system on atrial arrhythmogenic substrates and the incidence of atrial fibrillation in diabetic heart. International Heart Journal 2009 Sep;50(5):627-41.
24. Benichou T, Pereira B, Mermillod M, Tauveron I, Pfabigan D, Maqdasy S, Dutheil F. Heart rate variability in type 2 diabetes mellitus: a systematic review and meta-analysis. PLoS One 2018 Apr;13(4):e0195166.
25. Ziolo MT, Mohler PJ. Defining the role of oxidative stress in atrial fibrillation and diabetes. Journal of Cardiovascular Electrophysiology 2015 Feb;26(2):223-5.
26. Faria A, Persaud SJ. Cardiac oxidative stress in diabetes: mechanisms and therapeutic potential. Pharmacology & Therapeutics 2017 Apr;172:50-62.
27. Guo Y, Lip GYH, Apostolakis S. Inflammation in atrial fibrillation. Journal of the American College of Cardiology 2012 Dec;60(22):2263-70.
28. Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, Bigger T, Cushman W, Goff D, Soliman EZ, Thomas A, Papademetriou V. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). The American Journal of Cardiology 2014 Oct;114(8):1217-22.
29. Gu J, Fan YQ, Zhang JF, Wang CQ. Impact of long-term glycemic variability on development of atrial fibrillation in type 2 diabetic patients. The Anatolian Journal of Cardiology 2017 Dec;18(6):410-6.
30. Wang A, Green JB, Halperin JL, Piccini JP. Atrial fibrillation and diabetes mellitus: JACC review topic of the week. Journal of the American College of Cardiology 2019 Aug;74(8):1107-15.
31. Chang SH, Wu LS, Chiou MJ, Liu JR, Yu KH, Kuo CF, Wen MS, Chen WJ, Yeh YH, See LC. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovascular Diabetology 2014 Aug;13:123.
32. Zhang Z, Zhang X, Korantzopoulos P, Letsas KP, Tse G, Gong M, Meng L, Li G, Liu T. Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis. BMC Cardiovascular Disorders 2017 Apr;17(1):96.
33. Yu O, Azoulay L, Yin H, Filion KB, Suissa S. Sulfonylureas as initial treatment for type 2 diabetes and the risk of severe hypoglycemia. The American Journal of Medicine 2018 Mar;131(3):317.e11-22.
34. Liou YS, Yang FY, Chen HY, Jong GP. Antihyperglycemic drugs use and new-onset atrial fibrillation: a population-based nested case control study. PLoS One 2018 Aug;13(8):e0197245.
35. ORIGIN Trial Investigators; Gerstein H, Bosch J, Dagenais G, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia. The New England Journal of Medicine 2012 Jul;367(4):319-28.
36. Bell DSH, Goncalves E. Atrial fibrillation and type 2 diabetes: prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. Diabetes, Obesity & Metabolism 2019 Feb;21(2):210-7.
37. Newman JD, Vani AK, Aleman JO, Weintraub HS, Berger JS, Schwartzbard AZ. The changing landscape of diabetes therapy for cardiovascular risk reduction: JACC state-of-the-art review. Journal of the American College of Cardiology 2018 Oct;72(15):1856-69.
38. Patti G, Cavallari I, Andreotti F, Calabrò P, Cirillo P, Denas G, Galli M, Golia E, Maddaloni E, Marcucci R, Parato VM, Pengo V, Prisco D, Ricottini E, Renda G, Santilli F, Simeone P, De Caterina R; Working Group on Thrombosis of the Italian Society of Cardiology. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose lowering drugs. Nature Reviews. Cardiology 2019 Feb;16(2):113-30.
39. Fangel MV, Nielsen PB, Kristensen JK, Larsen TB, Overvad TF, Lip GYH, Jensen MB. Glycemic status and thromboembolic risk in patients with atrial fibrillation and type 2 diabetes mellitus: a Danish cohort study. Circulation, Arrhythmia and Electrophysiology 2019 May;12(5):e007030.
40. Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N, Reynolds K, Go AS. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. Journal of American Heart Association 2013 Jun;2(3):e000250.
41. Huxley RR, Alonso A, Lopez FL, Filion KB, Agarwal SK, Loehr LR, Soliman EZ, Pankow JP, Selvin E. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study. Heart (British Cardiac Society) 2012 Jan;98(2):133-8.
42. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal 2021 Feb;42(5):373-498.
43. Ben Zadok OI, Eisen A. Use of nonvitamin K oral anticoagulants in people with atrial fibrillation and diabetes mellitus. Diabetic Medicine 2018 May;35(5):548-56.
44. Patti G, Di Gioia G, Cavallari I, Nenna A. Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: a study-level meta-analysis of phase III randomized trials. Diabetes/Metabolism. Research & Reviews 2017 Mar;33(3):1-8.
45. Nelson WW, Choi JC, Vanderpoel J, Damaraju CV, Wildgoose P, Fields LE, Schein JR. Impact of co-morbidities and patient characteristics on international normalized ratio control over time in patients with nonvalvular atrial fibrillation. The American Journal of Cardiology 2013 Aug;112(4):509-12.
46. Lip GYH, Keshishian AV, Kang AL, Xiaoyan Li, Dhamane AD, Luo X, Balachander N, Rosenblatt L, Mardekian J, Nadkarni A, Pan X, Di Fusco M, Reeves ABG, Yuce H, Deitelzweig SB. Effectiveness and safety of oral anticoagulants in patients with nonvalvular atrial fibrillation and diabetes mellitus. Mayo Clinic Proceedings 2020 May;95(5):929-43.
47. Ezekowitz JA, Lewis BS, Lopes RD, Wojdyla DM, McMurray JJV, Hanna M, Atar D, Bahit C, Keltai M, Lopez-Sendon JL, Pais P, Ruzyllo W, Wallentin L, Granger CB, Alexander JH. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. European Heart Journal of Cardiovascular Pharmacotherapy 2015 Apr;1(2):86-94.
48. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. The New England Journal of Medicine 2013 Feb;368(8):699-708.
49. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, E Raskob GE, Weitz JI; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. The New England Journal of Medicine 2013 Aug;369(9):799-808.
50. Lu Y, Liu D, Feng Q, Liu Z. Diabetic nephropathy: perspective on extracellular vesicles. Frontiers in Immunology 2020 Jun;11:943.
51. Mahmood U, Healy HG, Kark A, Cameron A, Wang Z, Abeysekera R, Hoy WE. Spectrum (characteristics) of patients with chronic kidney disease (CKD) with increasing age in a major metropolitan renal service. BMC Nephrology 2017 Dec;18(1):372.
52. Zethelius B, Gudbjörnsdottir S, Eliasson B, Eeg-Olofsson K, Svensson AM, Cederholm J. Risk factors for atrial fibrillation in type 2 diabetes: report from the Swedish National Diabetes Register (NDR). Diabetologia 2015 Oct;58(10):2259-68.
53. Banerjee A, Fauchier L, Vourc’h P, Andres CR, Taillandier S, Halimi JM, Lip GYH. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 2014 Jun;145(6):1370-82.
54. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 2017 Mar;135(10):e146-603.
55. Potpara TS, Ferro CJ, Lip GYH. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nature Reviews. Nephrology 2018 May;14(5):337-51.
56. Yang F, Hellyer JA, Than C, Ullal AJ, Kaiser DW, Heidenreich PA, Hoang DD, Winkelmayer WC, Schmitt S, Frayne SM, Phibbs CS, Turakhia MP. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart (British Cardiac Society) 2016 Jun;103(11):818-26.
57. Alappan HR, Kaur G, Manzoor S, Navarrete J, O’Neill WC. Warfarin accelerates medial arterial calcification in humans. Arteriosclerosis, Thrombosis, and Vascular Biology 2020 May;40(5):1413-9.
58. Kimachi M, Furukawa TA, Kimachi K, Goto Y, Fukuma S, Fukuhara S. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. The Cochrane Database of Systematic Reviews 2017 Nov 6;11(11):CD011373.
59. Stanifer JW, Pokorney SD, Chertow GM, Hohnloser SH, Wojdyla DM, Garonzik S, Byon W, Hijazi Z, Lopes RD, Alexander JH, Wallentin L, Granger CB. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation 2020 Apr;141(17):1384-92.
60. Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clinical Pharmacokinetics 2019 Oct;58(10):1265-79.
61. Randhawa MS, Vishwanath R, Rai MP, Wang L, Randhawa AK, Abela G, Dhar G. Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease: a systematic review and meta-analysis. JAMA Network Open 2020 Apr;3(4):e202175.
62. Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K, Tilea A, Stack AG, Balkrishnan R, Yao X, Noseworthy PA, Shah ND, Saran R, Nallamothu BK. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 2018 Oct;138(15):1519-29.
63. de Ferranti SD, de Boer IH, Fonseca V, Fox CS, Golden SH, Lavie CJ, Magge SN, Marx N, McGuire DK, Orchard T, Zinman B, Eckel RH. Type 1 diabetes mellitus and cardiovascular disease. Circulation 2014 Sep;130(13):1110-30.
64. Mayer-Davis EJ, Lawrence JM, Dabelea D, Divers J, Isom S, Dolan L, Imperatore G, Linder B, Marcovina S, Pettitt DJ, Pihoker C, Saydah S, Wagenknecht L;SEARCH for Diabetes in Youth Study. Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012. The New England Journal of Medicine 2017 Apr;376(15):1419-29.
65. Schofield J, Ho J, Soran H. Cardiovascular risk in type 1 diabetes mellitus. Diabetes Therapy 2019 Jun;10(3):773-89.
66. Cai X, Li J, Cai W, Chen C, Ma J, Xie Z, Dong Y, Liu C, Xue R, Zhao J. Meta-analysis of type 1 diabetes mellitus and risk of cardiovascular disease. Journal of Diabetes and Its Complications 2021 Apr;35(4):107833.
67. Hallström S, Pivodic A, Rosengren A, Ólafsdóttir AF, Svensson AM, Lind M. Risk factors for atrial fibrillation in people with type 1 diabetes: an observational cohort study of 36,258 patients from the Swedish National Diabetes Registry. Diabetes Care 2019 Aug;42(8):1530-8.
68. Dahlqvist S, Rosengren A, Gudbjörnsdottir S, Pivodic A, Wedel H, Kosiborod M, Svensson AM, Lind M. Risk of atrial fibrillation in people with type 1 diabetes compared with matched controls from the general population: a prospective case-control study. The Lancet. Diabetes & Endocrinology 2017 Oct;5(10):799-807.
69. Fangel MV, Nielsen PB, Larsen TB, Christensen B, Overvad TF, Lip GYH, Goldhaber SZ, Jensen MB. Type 1 versus type 2 diabetes and thromboembolic risk in patients with atrial fibrillation: a Danish nationwide cohort study. International Journal of Cardiology 2018 Oct;268:137-42.
70. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. International Journal of Obesity 2008 Sep;32(9):1431-7.
71. Asad Z, Abbas M, Javed I, Korantzopoulos P, Stavrakis S. Obesity is associated with incident atrial fibrillation independent of gender: a meta-analysis. Journal of Cardiovascular Electrophysiology 2018 May;29(5):725-32.
72. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Maclehose R, Konety S, Alonso A. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 2011 Apr;123(14):1501-8.
73. Wong CX, Sullivan T, Sun MT, Mahajan R, Pathak RK, Middeldorp M, Twomey D, Ganesan AN, Rangnekar G, Roberts-Thomson KC, Lau DH, Sanders P. Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: a meta-analysis of 626,603 individuals in 51 studies. JACC. Critical Electrophysiology 2015 Jun;1(3):139-52.
74. Magnani JW, Hylek EM, Apovian CM. Obesity begets atrial fibrillation: a contemporary summary. Circulation 2013 Jul;128(4):401-5.
75. Lavie CJ, Pandey A, Lau DH, Alpert MA, Sanders P. Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise. Journal of the American College of Cardiology 2017 Oct;70(16):2022-35.
76. Goudis CA, Korantzopoulos P, Ntalas IV, Kallergis EM, Ketikoglou DG. Obesity and atrial fibrillation: a comprehensive review of the pathophysiological mechanisms and links. Journal of Cardiology 2015 Nov;66(5):361-9.
77. Thanigaimani S, McLennan E, Linz D, Mahajan R, Agbaedeng TA, Lee G, Kalman JM, Sanders P, Lau DH. Progression and reversibility of stretch induced atrial remodeling: characterization and clinical implications. Progress in Biophysics & Molecular Biology 2017 Nov;130(Pt B):376-86.
78. Loricchio ML, Cianfrocca C, Pasceri V, Bianconi L, Auriti A, Calo L, Lamberti F, Castro A, Pandozi C, Palamara A, Santini M. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion. The American Journal of Cardiology 2007 May;99(10):1421-4.
79. Abed HS, Samuel CS, Lau DH, Kelly DJ, Royce SG, Alasady M, Mahajan R, Kuklik P, Zhang Y, Brooks AG, Nelson AJ, Worthley SG, Abhayaratna WP, Kalman JM, Wittert GA, Prashanthan Sanders P. Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation. Heart Rhythm 2013 Jan;10(1):90-100.
80. Iwasaki YK, Shi Y, Benito B, Gillis MA, Mizuno K, Tardif JC, Nattel S. Determinants of atrial fibrillation in an animal model of obesity and acute obstructive sleep apnea. Heart Rhythm 2012 Sep;9(9):1409-16.e1.
81. Nattel S, Dobrev D. Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation. Nature Reviews. Cardiology 2016 Oct;13(10):575-90.
82. Guijian L, Jinchuan Y, Rongzeng D, Jun Q, Jun W, Wenqing Z. Impact of body mass index on atrial fibrillation recurrence: a meta-analysis of observational studies. Pacing and Clinical Electrophysiology 2013 Jun;36(6):748-56.
83. Pandey A, Gersh BJ, McGuire DK, Shrader P, Thomas L, Kowey PR, Mahaffey KW, Hylek E, Sun S, Burton P, Piccini J, Peterson E, Fonarow GC. Association of body mass index with care and outcomes in patients with atrial fibrillation: results from the ORBIT-AF registry. JACC. Electrophysiology 2016;2:355-63.
84. Badheka AO, Rathod A, Kizilbash MA, Garg N, Mohamad T, Afonso L, Jacob S. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. The American Journal of Medicine 2010 Jul;123(7):646-51.
85. Zhu W, Wan R, Liu F, Hu J, Huang, Li J, Hong K. Relation of body mass index with adverse outcomes among patients with atrial fibrillation: a meta-analysis and systematic review. Journal of the American Heart Association 2016 Sep;5(9):e004006.
86. Al-Rawahi M, Proletti R, Thansoulis G. Pericardial fat and atrial fibrillation: epidemiology, mechanisms and interventions. International Journal of Cardiology 2015 Sep;195:98-103.
87. Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, HalperinJL, Breithardt G, Singer DS, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KAA, Califf RM; ROCKET AF Steering Committee & Investigators. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF. Journal of the American Heart Association 2016 Mar;5(3):e002197.
88. Pandey A, Kim S, Moore C, Thomas L, Gersh B, Allen LA, Kowey PR, Mahaffey KW, Hylek E, Peterson ED, Piccini JP, Fonarow GC; ORBIT-AF Investigators and Patients. Predictors and prognostic implications of incident heart failure in patients with prevalent atrial fibrillation. JACC. Heart Failure 2017 Jan;5(1):44-52.
89. Lajous M, Banack HR, Kaufman JS, Hernán MA. Should patients with chronic disease be told to gain weight? The obesity paradox and selection bias. The American Journal of Medicine 2015 Apr;128(4):334-6.
90. Fioravanti F, Brisinda D, Sorbo AR, Fenici R. BMI reduction decreases AF recurrence rate in a Mediterranean cohort. Journal of the American College of Cardiology 2015 Nov;66(20):2264-5.
91. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Hendriks JML, Twomey D, Kalman JM, Abhayaratna WP, Lau DH, Sanders P. Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT study. Journal of the American College of Cardiology 2015 Sep;66(9):985-96.
92. Sandhu RK, Ezekowitz J, Andersson U, Alexander JH, Granger CB, Halvorsen S, Hanna M, Hijazi Z, Jansky P, Lopes RD, Wallentin L. The ’obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. European Heart Journal 2016 Oct;37(38):2869-78.
93. Wallace JL, Reaves AB, Tolley EA, Oliphant CS, Hutchison L, Alabdan NA, Sands CW, Self TH. Comparison of initial warfarin response in obese patients versus non-obese patients. Journal of Thrombosis and Thrombolysis 2013 Jul;36(1):96-101.
94. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine 2009 Sep;361(12):1139-51.
95. Patel MR, Mahaey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin IL, Hankey G, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England Journal of Medicine 2011 Sep;365(10):883-91.
96. Hohnloser SH, Fudim M, Alexander JH, Wojdyla DM, Ezekowitz JA, Hanna M, Atar D, Hijazi Z, Bahit MC, Al-Khatib SM, Lopez-Sendon JL, Wallentin L, Granger CB, Lopes RD. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight. Circulation 2019 May;139(20):2292-300.
97. Proietti M, Guiducci, E, Cheli P, Lip GYH. Is there an obesity paradox for outcomes in atrial fibrillation? A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant trials. Stroke 2017 Apr;48(4):857-66.
98. Deitelzweig S, Keshishian A, Kang A, Dhamane AD, Luo X, Li X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Di Fusco M, Reeves ABG, Yuce H, Lip GYH. Effectiveness and safety of oral anticoagulants among NVAF patients with obesity: insights from the ARISTOPHANES study. Journal of Clinical Medicine 2020 May;9(6):1633.

References

1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M, DeCleene N, Eagle KA, Emmons-Bell S, Feigin VL, Fernández-Solà J, Fowkes G, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum N, Koroshetz W, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Temesgen AM, Mokdad A, Moran AE, Muntner P, Narula J, Neal B, Ntsekhe M, de Oliveira GM, Otto C, Owolabi M, Pratt M, Rajagopalan S, Reitsma M, Ribeiro ALP, Rigotti N, Rodgers A, Sable C, Shakil S, Sliwa-Hahnle K, Stark B, Sundström J, Timpel P, Tleyjeh IM, Valgimigli M, Vos T, Whelton PK, Yacoub M, Zuhlke L, Murray C, Fuster V; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. Journal of the American College of Cardiology 2020 Dec;76(25):2982-3021.
2. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D’Agostino RB, Murabito JM, Kannel WB, Benjamin EJ. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003 Jun;107(23):2920-5.
3. Emdin CA, Wong CX, Hsiao AJ, Altman DG, Peters SA, Woodward M, Odutayo AA. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies. BMJ 2016 Jan;532:h7013.
4. Karam BS, Chavez-Moreno A, Koh W, Akar JG, Akar FG. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes. Cardiovascular Diabetology 2017 Sep;16(1):120.
5. Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GYH. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. Journal of Thrombosis and Haemostasis 2011 Jan;9(1):39-48.
6. Fumagalli S, Said SA, Laroche C, Gabbai D, Boni S, Marchionni N, Boriani G, Maggioni AP, Musialik-Lydka A, Sokal A, Petersen J, Crijns HJGM, Lip GYH; EORP-AF General Pilot Registry Investigators. Management and prognosis of atrial fibrillation in diabetic patients: an EORP-AF General Pilot Registry report. European Heart Journal. Cardiovascular Pharmacotherapy 2018 Jul;4(3):172-9.
7. Echouffo-Tcheugui JB, Shrader P, Thomas L, Gersh BJ, Kowey PR, Mahaffey KW, Hylek EM, Go AS, Peterson ED, Piccini JP, Fonarow GC. Care patterns and outcomes in atrial fibrillation patients with and without diabetes: ORBIT-AF registry. Journal of American College of Cardiology 2017 Sep;70(11):1325-35.
8. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994 Mar;271(11):840-4.
9. Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. The American Journal of Cardiology 2011 Jul;108(1):56-62.
10. Dublin S, Glazer NL, Smith NL, Psaty BM, Lumley T, Wiggins KL, Page RL, Heckbert SR. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. Journal of General Internal Medicine 2010 Aug;25(8):853-8.
11. Du X, Ninomiya T, de Galan B, Abadir E, Chalmers J, Pillai A, Woodward M, Cooper M, Harrap S, Hamet P, Poulter N, Lip GYH; ADVANCE Collaborative Group. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. European Heart Journal 2009 May;30(9):1128-35.
12. Russo I, Frangogiannis NG. Diabetes-associated cardiac fibrosis: cellular effectors, molecular mechanisms and therapeutic opportunities. Journal of Molecular and Cell Cardiology 2016 Jan;90:84-93.
13. Liu C, Fu H, Li J, Yang W, Cheng L, Liu T, Li G. Hyperglycemia aggravates atrial interstitial fibrosis, ionic remodeling and vulnerability to atrial fibrillation in diabetic rabbits. Anadolu Kardiyoloji Dergisi 2012 Nov;12(7):543-50.
14. Kato T, Yamashita T, Sekiguchi A, Tsuneda T, Sagara K, Takamura M, Kaneko S, Aizawa T, Fu LT. AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. Journal of Cardiovascular Electrophysiology 2008 Apr;19(4):415-20.
15. Jia G, Whaley-Connell A, Sowers JR. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia 2018 Jan;61(1):21-8.
16. Tiwari S, Schirmer H, Jacobsen BK, Hopstock LA, Nyrnes A, Heggelund G, Njølstad I, Mathiesen EB, Løchen ML. Association between diastolic dysfunction and future atrial fibrillation in the Tromsø Study from 1994 to 2010. Heart (British Cardiac Society) 2015 Aug;101(16):1302-8.
17. Watanabe M, Yokoshiki H, Mitsuyama H, Mizukami K, Ono T, Tsutsui H. Conduction and refractory disorders in the diabetic atrium. American Journal of Physiology. Heart and Circulatory Physiology 2012 Jul;303(1):H86-95.
18. Chao TF, Suenari K, Chang SL, Lin YJ, Lo LW, Hu YF, Tuan TC, Tai CT, Tsao HM, Li CH, Ueng KC, Wu TJ, Chen SA. Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose. The American Journal of Cardiology 2010 Dec;106(11):1615-20.
19. Ayhan S, Ozturk S, Alcelik A, Ozlu MF, Erdem A, Memioglu T, Ozdemir M, Yazici M. Atrial conduction time and atrial mechanical function in patients with impaired fasting glucose. Journal of Interventional Cardiac Electrophysiology 2012 Dec;35(3):247-52; discussion 252.
20. Demir K, Avci A, Kaya Z, Marakoglu K, Ceylan E, Yilmaz A, Ersecgin A, Armutlukuyu M, Altunkeser BB. Assessment of atrial electromechanical delay and P-wave dispersion in patients with type 2 diabetes mellitus. Journal of Cardiology 2016 Apr;67(4):378-83.
21. De Vos CB, Weijs B, Crijns HJGM, Cheriex EC, Palmans A, Habets J, Prins MH, Pisters R, Nieuwlaat R, Tieleman RG. Atrial tissue Doppler imaging for prediction of new-onset atrial fibrillation. Heart (British Cardiac Society) 2009 May;95(10):835-40.
22. Kuehl M, Stevens MJ. Cardiovascular autonomic neuropathies as complications of diabetes mellitus. Nature Reviews. Endocrinology 2012 Feb;8(7):405-16.
23. Otake H, Suzuki H, Honda T, Maruyama Y. Influences of autonomic nervous system on atrial arrhythmogenic substrates and the incidence of atrial fibrillation in diabetic heart. International Heart Journal 2009 Sep;50(5):627-41.
24. Benichou T, Pereira B, Mermillod M, Tauveron I, Pfabigan D, Maqdasy S, Dutheil F. Heart rate variability in type 2 diabetes mellitus: a systematic review and meta-analysis. PLoS One 2018 Apr;13(4):e0195166.
25. Ziolo MT, Mohler PJ. Defining the role of oxidative stress in atrial fibrillation and diabetes. Journal of Cardiovascular Electrophysiology 2015 Feb;26(2):223-5.
26. Faria A, Persaud SJ. Cardiac oxidative stress in diabetes: mechanisms and therapeutic potential. Pharmacology & Therapeutics 2017 Apr;172:50-62.
27. Guo Y, Lip GYH, Apostolakis S. Inflammation in atrial fibrillation. Journal of the American College of Cardiology 2012 Dec;60(22):2263-70.
28. Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, Bigger T, Cushman W, Goff D, Soliman EZ, Thomas A, Papademetriou V. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). The American Journal of Cardiology 2014 Oct;114(8):1217-22.
29. Gu J, Fan YQ, Zhang JF, Wang CQ. Impact of long-term glycemic variability on development of atrial fibrillation in type 2 diabetic patients. The Anatolian Journal of Cardiology 2017 Dec;18(6):410-6.
30. Wang A, Green JB, Halperin JL, Piccini JP. Atrial fibrillation and diabetes mellitus: JACC review topic of the week. Journal of the American College of Cardiology 2019 Aug;74(8):1107-15.
31. Chang SH, Wu LS, Chiou MJ, Liu JR, Yu KH, Kuo CF, Wen MS, Chen WJ, Yeh YH, See LC. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovascular Diabetology 2014 Aug;13:123.
32. Zhang Z, Zhang X, Korantzopoulos P, Letsas KP, Tse G, Gong M, Meng L, Li G, Liu T. Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis. BMC Cardiovascular Disorders 2017 Apr;17(1):96.
33. Yu O, Azoulay L, Yin H, Filion KB, Suissa S. Sulfonylureas as initial treatment for type 2 diabetes and the risk of severe hypoglycemia. The American Journal of Medicine 2018 Mar;131(3):317.e11-22.
34. Liou YS, Yang FY, Chen HY, Jong GP. Antihyperglycemic drugs use and new-onset atrial fibrillation: a population-based nested case control study. PLoS One 2018 Aug;13(8):e0197245.
35. ORIGIN Trial Investigators; Gerstein H, Bosch J, Dagenais G, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia. The New England Journal of Medicine 2012 Jul;367(4):319-28.
36. Bell DSH, Goncalves E. Atrial fibrillation and type 2 diabetes: prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. Diabetes, Obesity & Metabolism 2019 Feb;21(2):210-7.
37. Newman JD, Vani AK, Aleman JO, Weintraub HS, Berger JS, Schwartzbard AZ. The changing landscape of diabetes therapy for cardiovascular risk reduction: JACC state-of-the-art review. Journal of the American College of Cardiology 2018 Oct;72(15):1856-69.
38. Patti G, Cavallari I, Andreotti F, Calabrò P, Cirillo P, Denas G, Galli M, Golia E, Maddaloni E, Marcucci R, Parato VM, Pengo V, Prisco D, Ricottini E, Renda G, Santilli F, Simeone P, De Caterina R; Working Group on Thrombosis of the Italian Society of Cardiology. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose lowering drugs. Nature Reviews. Cardiology 2019 Feb;16(2):113-30.
39. Fangel MV, Nielsen PB, Kristensen JK, Larsen TB, Overvad TF, Lip GYH, Jensen MB. Glycemic status and thromboembolic risk in patients with atrial fibrillation and type 2 diabetes mellitus: a Danish cohort study. Circulation, Arrhythmia and Electrophysiology 2019 May;12(5):e007030.
40. Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N, Reynolds K, Go AS. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. Journal of American Heart Association 2013 Jun;2(3):e000250.
41. Huxley RR, Alonso A, Lopez FL, Filion KB, Agarwal SK, Loehr LR, Soliman EZ, Pankow JP, Selvin E. Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study. Heart (British Cardiac Society) 2012 Jan;98(2):133-8.
42. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal 2021 Feb;42(5):373-498.
43. Ben Zadok OI, Eisen A. Use of nonvitamin K oral anticoagulants in people with atrial fibrillation and diabetes mellitus. Diabetic Medicine 2018 May;35(5):548-56.
44. Patti G, Di Gioia G, Cavallari I, Nenna A. Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: a study-level meta-analysis of phase III randomized trials. Diabetes/Metabolism. Research & Reviews 2017 Mar;33(3):1-8.
45. Nelson WW, Choi JC, Vanderpoel J, Damaraju CV, Wildgoose P, Fields LE, Schein JR. Impact of co-morbidities and patient characteristics on international normalized ratio control over time in patients with nonvalvular atrial fibrillation. The American Journal of Cardiology 2013 Aug;112(4):509-12.
46. Lip GYH, Keshishian AV, Kang AL, Xiaoyan Li, Dhamane AD, Luo X, Balachander N, Rosenblatt L, Mardekian J, Nadkarni A, Pan X, Di Fusco M, Reeves ABG, Yuce H, Deitelzweig SB. Effectiveness and safety of oral anticoagulants in patients with nonvalvular atrial fibrillation and diabetes mellitus. Mayo Clinic Proceedings 2020 May;95(5):929-43.
47. Ezekowitz JA, Lewis BS, Lopes RD, Wojdyla DM, McMurray JJV, Hanna M, Atar D, Bahit C, Keltai M, Lopez-Sendon JL, Pais P, Ruzyllo W, Wallentin L, Granger CB, Alexander JH. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. European Heart Journal of Cardiovascular Pharmacotherapy 2015 Apr;1(2):86-94.
48. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. The New England Journal of Medicine 2013 Feb;368(8):699-708.
49. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, E Raskob GE, Weitz JI; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. The New England Journal of Medicine 2013 Aug;369(9):799-808.
50. Lu Y, Liu D, Feng Q, Liu Z. Diabetic nephropathy: perspective on extracellular vesicles. Frontiers in Immunology 2020 Jun;11:943.
51. Mahmood U, Healy HG, Kark A, Cameron A, Wang Z, Abeysekera R, Hoy WE. Spectrum (characteristics) of patients with chronic kidney disease (CKD) with increasing age in a major metropolitan renal service. BMC Nephrology 2017 Dec;18(1):372.
52. Zethelius B, Gudbjörnsdottir S, Eliasson B, Eeg-Olofsson K, Svensson AM, Cederholm J. Risk factors for atrial fibrillation in type 2 diabetes: report from the Swedish National Diabetes Register (NDR). Diabetologia 2015 Oct;58(10):2259-68.
53. Banerjee A, Fauchier L, Vourc’h P, Andres CR, Taillandier S, Halimi JM, Lip GYH. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 2014 Jun;145(6):1370-82.
54. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 2017 Mar;135(10):e146-603.
55. Potpara TS, Ferro CJ, Lip GYH. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nature Reviews. Nephrology 2018 May;14(5):337-51.
56. Yang F, Hellyer JA, Than C, Ullal AJ, Kaiser DW, Heidenreich PA, Hoang DD, Winkelmayer WC, Schmitt S, Frayne SM, Phibbs CS, Turakhia MP. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart (British Cardiac Society) 2016 Jun;103(11):818-26.
57. Alappan HR, Kaur G, Manzoor S, Navarrete J, O’Neill WC. Warfarin accelerates medial arterial calcification in humans. Arteriosclerosis, Thrombosis, and Vascular Biology 2020 May;40(5):1413-9.
58. Kimachi M, Furukawa TA, Kimachi K, Goto Y, Fukuma S, Fukuhara S. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. The Cochrane Database of Systematic Reviews 2017 Nov 6;11(11):CD011373.
59. Stanifer JW, Pokorney SD, Chertow GM, Hohnloser SH, Wojdyla DM, Garonzik S, Byon W, Hijazi Z, Lopes RD, Alexander JH, Wallentin L, Granger CB. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation 2020 Apr;141(17):1384-92.
60. Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clinical Pharmacokinetics 2019 Oct;58(10):1265-79.
61. Randhawa MS, Vishwanath R, Rai MP, Wang L, Randhawa AK, Abela G, Dhar G. Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease: a systematic review and meta-analysis. JAMA Network Open 2020 Apr;3(4):e202175.
62. Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K, Tilea A, Stack AG, Balkrishnan R, Yao X, Noseworthy PA, Shah ND, Saran R, Nallamothu BK. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 2018 Oct;138(15):1519-29.
63. de Ferranti SD, de Boer IH, Fonseca V, Fox CS, Golden SH, Lavie CJ, Magge SN, Marx N, McGuire DK, Orchard T, Zinman B, Eckel RH. Type 1 diabetes mellitus and cardiovascular disease. Circulation 2014 Sep;130(13):1110-30.
64. Mayer-Davis EJ, Lawrence JM, Dabelea D, Divers J, Isom S, Dolan L, Imperatore G, Linder B, Marcovina S, Pettitt DJ, Pihoker C, Saydah S, Wagenknecht L;SEARCH for Diabetes in Youth Study. Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012. The New England Journal of Medicine 2017 Apr;376(15):1419-29.
65. Schofield J, Ho J, Soran H. Cardiovascular risk in type 1 diabetes mellitus. Diabetes Therapy 2019 Jun;10(3):773-89.
66. Cai X, Li J, Cai W, Chen C, Ma J, Xie Z, Dong Y, Liu C, Xue R, Zhao J. Meta-analysis of type 1 diabetes mellitus and risk of cardiovascular disease. Journal of Diabetes and Its Complications 2021 Apr;35(4):107833.
67. Hallström S, Pivodic A, Rosengren A, Ólafsdóttir AF, Svensson AM, Lind M. Risk factors for atrial fibrillation in people with type 1 diabetes: an observational cohort study of 36,258 patients from the Swedish National Diabetes Registry. Diabetes Care 2019 Aug;42(8):1530-8.
68. Dahlqvist S, Rosengren A, Gudbjörnsdottir S, Pivodic A, Wedel H, Kosiborod M, Svensson AM, Lind M. Risk of atrial fibrillation in people with type 1 diabetes compared with matched controls from the general population: a prospective case-control study. The Lancet. Diabetes & Endocrinology 2017 Oct;5(10):799-807.
69. Fangel MV, Nielsen PB, Larsen TB, Christensen B, Overvad TF, Lip GYH, Goldhaber SZ, Jensen MB. Type 1 versus type 2 diabetes and thromboembolic risk in patients with atrial fibrillation: a Danish nationwide cohort study. International Journal of Cardiology 2018 Oct;268:137-42.
70. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. International Journal of Obesity 2008 Sep;32(9):1431-7.
71. Asad Z, Abbas M, Javed I, Korantzopoulos P, Stavrakis S. Obesity is associated with incident atrial fibrillation independent of gender: a meta-analysis. Journal of Cardiovascular Electrophysiology 2018 May;29(5):725-32.
72. Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Maclehose R, Konety S, Alonso A. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 2011 Apr;123(14):1501-8.
73. Wong CX, Sullivan T, Sun MT, Mahajan R, Pathak RK, Middeldorp M, Twomey D, Ganesan AN, Rangnekar G, Roberts-Thomson KC, Lau DH, Sanders P. Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: a meta-analysis of 626,603 individuals in 51 studies. JACC. Critical Electrophysiology 2015 Jun;1(3):139-52.
74. Magnani JW, Hylek EM, Apovian CM. Obesity begets atrial fibrillation: a contemporary summary. Circulation 2013 Jul;128(4):401-5.
75. Lavie CJ, Pandey A, Lau DH, Alpert MA, Sanders P. Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise. Journal of the American College of Cardiology 2017 Oct;70(16):2022-35.
76. Goudis CA, Korantzopoulos P, Ntalas IV, Kallergis EM, Ketikoglou DG. Obesity and atrial fibrillation: a comprehensive review of the pathophysiological mechanisms and links. Journal of Cardiology 2015 Nov;66(5):361-9.
77. Thanigaimani S, McLennan E, Linz D, Mahajan R, Agbaedeng TA, Lee G, Kalman JM, Sanders P, Lau DH. Progression and reversibility of stretch induced atrial remodeling: characterization and clinical implications. Progress in Biophysics & Molecular Biology 2017 Nov;130(Pt B):376-86.
78. Loricchio ML, Cianfrocca C, Pasceri V, Bianconi L, Auriti A, Calo L, Lamberti F, Castro A, Pandozi C, Palamara A, Santini M. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion. The American Journal of Cardiology 2007 May;99(10):1421-4.
79. Abed HS, Samuel CS, Lau DH, Kelly DJ, Royce SG, Alasady M, Mahajan R, Kuklik P, Zhang Y, Brooks AG, Nelson AJ, Worthley SG, Abhayaratna WP, Kalman JM, Wittert GA, Prashanthan Sanders P. Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation. Heart Rhythm 2013 Jan;10(1):90-100.
80. Iwasaki YK, Shi Y, Benito B, Gillis MA, Mizuno K, Tardif JC, Nattel S. Determinants of atrial fibrillation in an animal model of obesity and acute obstructive sleep apnea. Heart Rhythm 2012 Sep;9(9):1409-16.e1.
81. Nattel S, Dobrev D. Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation. Nature Reviews. Cardiology 2016 Oct;13(10):575-90.
82. Guijian L, Jinchuan Y, Rongzeng D, Jun Q, Jun W, Wenqing Z. Impact of body mass index on atrial fibrillation recurrence: a meta-analysis of observational studies. Pacing and Clinical Electrophysiology 2013 Jun;36(6):748-56.
83. Pandey A, Gersh BJ, McGuire DK, Shrader P, Thomas L, Kowey PR, Mahaffey KW, Hylek E, Sun S, Burton P, Piccini J, Peterson E, Fonarow GC. Association of body mass index with care and outcomes in patients with atrial fibrillation: results from the ORBIT-AF registry. JACC. Electrophysiology 2016;2:355-63.
84. Badheka AO, Rathod A, Kizilbash MA, Garg N, Mohamad T, Afonso L, Jacob S. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox. The American Journal of Medicine 2010 Jul;123(7):646-51.
85. Zhu W, Wan R, Liu F, Hu J, Huang, Li J, Hong K. Relation of body mass index with adverse outcomes among patients with atrial fibrillation: a meta-analysis and systematic review. Journal of the American Heart Association 2016 Sep;5(9):e004006.
86. Al-Rawahi M, Proletti R, Thansoulis G. Pericardial fat and atrial fibrillation: epidemiology, mechanisms and interventions. International Journal of Cardiology 2015 Sep;195:98-103.
87. Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, HalperinJL, Breithardt G, Singer DS, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KAA, Califf RM; ROCKET AF Steering Committee & Investigators. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF. Journal of the American Heart Association 2016 Mar;5(3):e002197.
88. Pandey A, Kim S, Moore C, Thomas L, Gersh B, Allen LA, Kowey PR, Mahaffey KW, Hylek E, Peterson ED, Piccini JP, Fonarow GC; ORBIT-AF Investigators and Patients. Predictors and prognostic implications of incident heart failure in patients with prevalent atrial fibrillation. JACC. Heart Failure 2017 Jan;5(1):44-52.
89. Lajous M, Banack HR, Kaufman JS, Hernán MA. Should patients with chronic disease be told to gain weight? The obesity paradox and selection bias. The American Journal of Medicine 2015 Apr;128(4):334-6.
90. Fioravanti F, Brisinda D, Sorbo AR, Fenici R. BMI reduction decreases AF recurrence rate in a Mediterranean cohort. Journal of the American College of Cardiology 2015 Nov;66(20):2264-5.
91. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Hendriks JML, Twomey D, Kalman JM, Abhayaratna WP, Lau DH, Sanders P. Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT study. Journal of the American College of Cardiology 2015 Sep;66(9):985-96.
92. Sandhu RK, Ezekowitz J, Andersson U, Alexander JH, Granger CB, Halvorsen S, Hanna M, Hijazi Z, Jansky P, Lopes RD, Wallentin L. The ’obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. European Heart Journal 2016 Oct;37(38):2869-78.
93. Wallace JL, Reaves AB, Tolley EA, Oliphant CS, Hutchison L, Alabdan NA, Sands CW, Self TH. Comparison of initial warfarin response in obese patients versus non-obese patients. Journal of Thrombosis and Thrombolysis 2013 Jul;36(1):96-101.
94. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine 2009 Sep;361(12):1139-51.
95. Patel MR, Mahaey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin IL, Hankey G, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England Journal of Medicine 2011 Sep;365(10):883-91.
96. Hohnloser SH, Fudim M, Alexander JH, Wojdyla DM, Ezekowitz JA, Hanna M, Atar D, Hijazi Z, Bahit MC, Al-Khatib SM, Lopez-Sendon JL, Wallentin L, Granger CB, Lopes RD. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight. Circulation 2019 May;139(20):2292-300.
97. Proietti M, Guiducci, E, Cheli P, Lip GYH. Is there an obesity paradox for outcomes in atrial fibrillation? A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant trials. Stroke 2017 Apr;48(4):857-66.
98. Deitelzweig S, Keshishian A, Kang A, Dhamane AD, Luo X, Li X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Di Fusco M, Reeves ABG, Yuce H, Lip GYH. Effectiveness and safety of oral anticoagulants among NVAF patients with obesity: insights from the ARISTOPHANES study. Journal of Clinical Medicine 2020 May;9(6):1633.

  

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]